ORLive Presents: Myxomatous Mitral Regurgitation, a Simplified, Physiologic Repair
The newest addition to Edwards’ comprehensive valve repair line, the Edwards Myxo ETlogix annuloplasty ring, is designed specifically to treat patients with myxomatous disease, a degenerative condition resulting in excess mitral valve leaflet tissue. Patients with this disease are often younger and their repair may be quite complex. They are frequently treated with mechanical valves, leading to lifelong anticoagulation therapy and its associated complications and lifestyle compromises. The Myxo ring offers surgeons a better option for these patients. During this live webcast on www.OR-Live.com viewers can send questions directly to the surgeons for an on camera response.
“The combination of the new Myxo ETlogix ring and widely practiced repair techniques makes even the most complex myxomatous repair cases more straight-forward and reproducible,” said Dr. Patrick McCarthy, chief of the Cardiothoracic Surgery Division, co-director of the Bluhm Cardiovascular Institute, Northwestern University, and a paid consultant to Edwards Lifesciences (NYSE: EW). “This should offer surgeons a preferable alternative to a mechanical valve which requires lifelong anticoagulation therapy.”
Visit: http://www.or-live.com/edwards/1895 now to learn more and view a program preview. VNR http://www.or-live.com/rams/edl-1895-mkw-q.ram
Video-Link Available: http://www.marketwire.com/mw/frame_mw?attachid=490504
Contact: Alex Fraser Director of Marketing slp3D, Inc. / OR-Live 860-953-2900 x 214 Contact via http://www.marketwire.com/mw/emailprcntct?id=348122C8347D82E2
SOURCE: slp3D